HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Glycine antidumping

This article was originally published in The Rose Sheet

Executive Summary

International Trade Administration continues antidumping duty order on China. ITC determines revocation of the order "would be likely to lead to continuation or recurrence of material injury to an industry" in the U.S. The order was effective with publication of a Federal Register notice July 25. Glycine is used in hair conditioners, skin care preps and permanent wave products. A review was announced in February (1"The Rose Sheet" Feb. 7, In Brief)

You may also be interested in...



Glycine antidumping

Cosmetics conditioning ingredient import regulation from China undergoes five year review by the International Trade Commission to determine whether revocation of the 1995 antidumping measure would lead to "material injury" in the U.S., the agency states in the Feb. 3 Federal Register. Glycine is used in products such as hair conditioners, skin care preparations and permanent wave products. Comments are due March 22

OCA Applauds Organic Board's Recommendation To USDA: "Outlaw Nanotech"

With a push from the Organic Consumers Association, the National Organic Standards Board is recommending that the use of nanotechnology be strictly prohibited from products certified under the National Organic Program

Beauty Claims Inch Closer To Pharma As Cosmeceutical Sector Expands

Though global market-size estimates differ, analysts at SupplySide West 2010 in Las Vegas agreed that cosmeceuticals remain a promising growth vehicle

Latest Headlines
See All
UsernamePublicRestriction

Register

RS008284

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel